Newly launched Unlock Health, a partnership involving a Houston agency, delivers consulting, marketing, and technology services to health care organizations. Photo via Getty Images

Houston-based digital and creative agency DECODE is now part of a new health care technology and services platform called Unlock Health.

The new platform came about through the combination of DECODE, which serves the health care market, and Bradenton, Florida-based Eruptr, an agency specializing in digital marketing for the health care sector.

The Nashville-based platform is backed by Greenwich, Connecticut-based Amulet Capital Partners, a private equity firm that focuses solely on the health care sector, and New York City-based Athyrium Capital Management, an asset manager that concentrates on the health care sector.

Unlock Health delivers consulting, marketing, and technology services to customers such as health care systems, physician groups, and specialty health care providers. Brandon Edwards is CEO of the new platform, and Shannon McIntyre Hooper is president.

DECODE and Eruptr will continue to operate under their respective brands and be led by their existing management teams. Houston native Kathleen Perley remains aboard as CEO of DECODE, which she founded in 2013.

“With the launch of Unlock Health, we will have the benefits of increased scale and a broader range of market-leading services and expertise to support clients as they navigate and compete in a rapidly evolving industry,” Perley says in a news release.

DECODE saw revenue three-year growth of 131 percent from 2019 to 2021, making it one of the country’s fastest-growing private companies during that span.

The new venture employs about 120 people.

“We recognize the tremendous potential and impact a trusted one-stop provider of integrated marketing, consulting, and tech enablement can have in breaking down long-standing barriers for health care organizations,” Edwards says.

He adds that the new platform will remove “the guesswork from growth” and help health care organizations “succeed now and in the future.”

It might come as no surprise that Houston, home to the largest medical center in the world, has many impressive health startups. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

4 Houston health startups to look out for

Health tech

Houston's growing life sciences industry has been a topic of discussion of late — and it's pretty obvious why.

In March, Houston was named the No. 2 top city for an emerging life sciences market, according to CBRE data. Houston was also named the No. 2 city for STEM jobs, per a report from American Enterprise Institute's Housing Center, which cited the city's growing life science industry as a factor. Even Amazon, which recently opened a Tech Hub in Houston, credited the city's life sciences as a reason for Houston's selection.

In fact, according to a report from the Greater Houston Partnership, Houston has over a fifth of the nation's clinical trials last year. With health care innovation abound in town, here are four startups to keep an eye on.

Integrated Bionics

Stephane Smith wants his company, Integrated Bionics, and its sports tech sensor to be a big win for Houston. Courtesy of Integrated Bionics

It may have taken a couple attempts, but Stephane Smith has created a booming sports wearable business that ships products across the United States and the world. Integrate Bionics produces the Titan Sensor — a wearable device that syncs GPS with video and provides athletic metrics at an attainable price. Most of the company's customers are soccer teams primarily in the collegiate space — with some professional and even youth teams. Smith says the company has a firm footing within soccer because that's where this technology really started.

With fresh funds from Houston-based Work America Capital, Integrated Bionics is on a path to scale and grow its product's capabilities.

"We're going to continue relentless innovation — doing things that no one is expecting and helping coaches with things not even on the radar," Smith tells InnovationMap. "We'll going to be rolling out new capabilities and features that have traditionally been relegated to high-end systems or that haven't even existed before."

Read more about Integrated Bionics here.

InformAI

InformAI can use its data technology to help doctors with preventative care and diagnoses. Courtesy of InformAI

Health care is one of the industries where data management might get a "needs improvement" on its report card. Hospitals everywhere have tons of data, and they aren't using it to their full potential. Houston-based InformAI is looking to change this within the Texas Medical Center.

Jim Havelka, founder and CEO, started the company in 2017, and created a new technology that allows hospitals and medical establishments better access to its own data – which translates into more effective diagnoses and preventative care. Havelka saw a need within the medical industry for this type of service.

"There were several things missing," says Havelka. "One was access to very large data sets, because it wasn't really until the last five or 10 years that digitalization of data, especially in the healthcare vertical became more widespread and available in a format that's usable. The second convergence was the technology, the ability to process very large data sets."

Read more about InformAI here.

Mental Health Match

Ryan Schwartz realized online dating was easier than finding a therapist. He created a tool to change that. Courtesy of Mental Health Match

If only finding a therapist was as easy as finding a date in a world where dating apps are a dime a dozen. Ryan Schwartz realized as he sat in a coffee shop with a friend making a connection online, it should be that easy.

"In two minutes she could have a profile matching her with a partner potentially for the rest of her life and I was sitting there for hours and hours trying to find a therapist," he recalls. "I thought it should be easier to find a therapist than a life partner. That's what sent me on my journey."

That journey reached a watershed last month when Schwartz launched Mental Health Match, a website designed to pair patients with their ideal therapist. The idea gained traction as Schwartz described it to people he met and found that many said they had experienced similar difficulties in finding the right practitioner for their needs.

Read more about Mental Health Match here.

Lazarus 3D

Lazarus 3D is using 3D printing to help advance surgeons' skills. Photo via laz3d.com

It's 2019 and surgeons are still using the same training tools they have used for decades: produce.

Two Baylor College of Medicine-educated doctors thought that sewing up grapes and slicing bananas was a bit antiquated. Drs. Jacques Zaneveld and Smriti Agrawal Zaneveld founded Lazarus3D to build a better training model — and layer by layer, they created models of abs and ribs and even hearts with a 3D printer.

"We adapted pre-existing 3D printing technology in a novel proprietary way that allows us to, overnight, build soft, silicone or hydrogel models of human anatomy," says Jacques, who serves as CEO. "They can be treated just like real tissue."

Read more about Lazarus 3D here.

TMCx is introducing a new opportunity for early stage health tech ideas. Courtesy of TMCx

TMC Innovation Institute introduces new early stage programming opportunities for health care workers

Alpha ideas

While the Texas Medical Center's accelerator, TMCx, accepts two cohorts of health care startups a year at various stages of development, the program isn't optimized for early stage ideas for companies.

Yet for years, the TMC Innovation Institute team has fielded questions from budding entrepreneurs over cold emails — and even LinkedIn.

TMC will launch a new program for these early stage ideas called TMCalpha. Lance Black, associate director of TMCx, announced the program at TMCx's Demo Day on Thursday, June 6.

"Alpha is the first letter in the Greek alphabet. It represents the beginning — the first step in your journey," Black says.

Through monthly events, TMC-affiliated entrepreneurs can meet with the TMCx team, learn startup best practices, pitch to professionals, and receive one-on-one advice.

"It's our mission to support those members in the TMC — those employees, those physicians, those affiliates — that are knee-deep in the problems and have ideas for solutions," he adds.

The details of the program have yet to be revealed, and Black suggested interested parties subscribe to their newsletter.

"Too many good ideas go undeveloped because people don't have a place to turn or know who to talk to," Black says. "Now they do."

Before and after the announcement, 19 different startups pitched to the crowd at the TMC Innovation Institute, representing the end of the accelerator program. The 2019 Digital Health cohort represented the eighth — and most international — cohort within the program.

Three companies within the cohort have announced completed raises totaling over $10 million. However, according to the pitches, that figure is likely even higher.

Houston-based Galen Data is growing its clientbase and just formed two new partnerships with medical device companies. Photo via galendata.com

Houston health care data company grows with new medical device partnerships

Digitizing health

Educated as an engineer, Chris DuPont has stepped outside his professional comfort zone to generate funding for his Houston-based startup, Galen Data Inc. DuPont's pool of technical contacts in Houston is "wide and deep," he says, but his pool of financial contacts had been shallow.

Overcoming obstacles in Houston's business waters, DuPont has raised two rounds of angel funding — he declines to say how much — that have enabled Galen Data to develop and market its cloud-based platform for connecting medical devices to the internet, including pacemakers and glucose monitors. DuPont is the startup's co-founder and CEO. Galen Data's platform meets compliance standards set by the U.S. Food and Drug Administration (FDA), the Health Insurance Portability and Accountability Act of 1996 (HIPPA), cybersecurity organizations, and others.

Galen Data's patent-pending technology lets medical device manufacturers tailor the cloud-based software to their unique needs. DuPont says his company's software is geared toward medical devices that are outside, not inside, hospitals and other healthcare facilities. He declines to divulge how many customers the startup has.

Among the startup's customers is San Clemente, California-based Fresca Medical Inc., developer of a device designed to treat sleep apnea.

DuPont says his company's software allows Fresca to perform such tasks as proactively diagnosing problems with the battery in a sleep apnea device or collecting patient data to back up insurance claims. The software even can monitor trends among various medical devices, he says. Galen Data also is helping Fresca develop its mobile app for patients.

Another customer is Friendswood-based Spark Biomedical Inc., developer of a smartphone-connected device, called a neurostimulator, that eases the symptoms of withdrawal from highly addictive opioids.

Hatched within Houston-based Tietronix Software Inc., DuPont's previous employer, Galen Data launched in 2016 but didn't roll out its first product until 2018.

Galen Data's emergence comes as the market for internet-connected mobile health apps keeps growing. One forecast envisions the global space for mobile health exceeding $94 billion by 2023.

"We want to be at the forefront of that technology curve," DuPont says. "We might be six months early, we might be a year early, but it's starting to happen."

Galen Data vies for customers in a largely untapped market, since the majority of medical devices still aren't connected to the internet, according to DuPont. As a whole, medical device makers have been reluctant to delve into connectivity, given the compliance headaches, DuPont says. That's where Galen Data steps in. It's the startup's job, he says, to ensure its tech platform adheres to myriad compliance regulations.

DuPont says a medical device manufacturer easily could spend $250,000 to $500,000 to create its own compliant, connected tech platform similar to Galen Data's offering — and that doesn't include ongoing operational expenses. Galen Data's platform delivers the same benefits at a fraction of that cost, he says.

The startup strives to accomplish its mission with minimal staffing. Between full-timers (including the three co-founders) and contractors, Galen Data employs fewer than 10 people, DuPont says. As needed, Galen Data taps the software development talent at Tietronix, which owns a minority stake in the startup, according to DuPont.

"I'm very, very capital-efficient with our cash," he says. "I don't like layoffs. We'll never have planned layoffs."

If Galen Data continues to achieve its financial goals (it's not profitable yet), DuPont says, the company's workforce could total 20 to 30 within three years. He foresees opening satellite offices in Austin (a tech hub) and Boston (a life sciences hub) at some point.

As for additional products, DuPont wants to eventually build on Galen Data's existing platform by paving the way for data to be securely transferred from medical devices to electronic medical records.

Anchored in Houston, Galen Data hopes to be a player in what DuPont calls "the next biotech corridor of the United States," encompassing not just Houston but Galveston, Austin, Dallas, and San Antonio.

For Galen Data to thrive in that environment, though, it must conquer what DuPont classifies as his biggest hurdle: raising money from investors in a region rooted in the oil and gas industry. In the first quarter of 2019, Houston startups collected less than 6 percent of the venture capital reported throughout Texas — far below what startups in Austin and Dallas reaped during the same period.

Ramping up investment in Galen Data will require educating local investors about the promising potential of the medical device sector, DuPont says. Meanwhile, he's begun hunting for funding outside Texas.

"It's challenging for a startup to raise money in Houston," says DuPont, who praises local entrepreneurs for their support of Galen Data. "We've done it, but it's been hard."

"If Galen is super successful, hopefully we can invest in other early stage companies," DuPont adds. "That's part of the vision."

Galen Concept Videowww.youtube.com

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Texas tops ranking of best state for investors in new report

by the numbers

Texas ranks third on a new list of the best states for investors and startups.

Investment platform BrokerChooser weighed five factors to come up with its ranking:

  • 2024 Google search volume for terms related to investing
  • Number of investors
  • Number of businesses receiving investments in 2024
  • Total amount of capital invested in businesses in 2024
  • Percentage change in amount of investment from 2019 to 2024

Based on those figures, provided mostly by Crunchbase, Texas sits at No. 3 on the list, behind No. 1 California and No. 2 New York.

Especially noteworthy for Texas is its investment total for 2024: more than $164.5 billion. From 2019 to 2024, the state saw a 440 percent jump in business investments, according to BrokerChooser. The same percentages are 204 percent for California and 396 percent for New York.

“There is definitely development and diversification in the American investment landscape, with impressive growth in areas that used to fly under the radar,” says Adam Nasli, head analyst at BrokerChooser.

According to Crunchbase, funding for Texas startups is off to a strong start in 2025. In the first three months of this year, venture capital investors poured nearly $2.9 billion into Lone Star State companies, Crunchbase data shows. Crunchbase attributes that healthy dollar amount to “enthusiasm around cybersecurity, defense tech, robotics, and de-extincting mammoths.”

During the first quarter of this year, roughly two-thirds of VC funding in Texas went to just five companies, says Crunchbase. Those companies are Austin-based Apptronik, Austin-based Colossal Biosciences, Dallas-based Island, Austin-based NinjaOne, and Austin-based Saronic.

Autonomous truck company rolls out driverless Houston-Dallas route

up and running

Houston is helping drive the evolution of self-driving freight trucks.

In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27.

Close to half of all truck freight in Texas moves along I-45 between Houston and Dallas.

“Now, we are the first company to successfully and safely operate a commercial driverless trucking service on public roads. Riding in the back seat for our inaugural trip was an honor of a lifetime – the Aurora Driver performed perfectly and it’s a moment I’ll never forget,” Chris Urmson, CEO and co-founder of Pittsburgh-based Aurora, said in a news release.

Aurora produces software that controls autonomous vehicles and is known for its flagship product, the Aurora Driver. The software is installed in Volvo and Paccar trucks, the latter of which includes brands like Kenworth and Peterbilt.

Aurora previously hauled more than 75 loads per week under the supervision of vehicle operators from Houston to Dallas and Fort Worth to El Paso for customers in its pilot project, including FedEx, Uber Freight and Werner. To date, it has completed over 1,200 miles without a driver.

The company launched its new Houston to Dallas route with customers Uber Freight and Hirschbach Motor Lines, which ran supervised commercial pilots with Aurora.

“Transforming an old school industry like trucking is never easy, but we can’t ignore the safety and efficiency benefits this technology can deliver. Autonomous trucks aren’t just going to help grow our business – they’re also going to give our drivers better lives by handling the lengthier and less desirable routes,” Richard Stocking, CEO of Hirschbach Motor Lines, added in the statement.

The company plans to expand its service to El Paso and Phoenix by the end of 2025.

“These new, autonomous semis on the I-45 corridor will efficiently move products, create jobs, and help make our roadways safer,” Gov. Greg Abbott added in the release. “Texas offers businesses the freedom to succeed, and the Aurora Driver will further spur economic growth and job creation in Texas. Together through innovation, we will build a stronger, more prosperous Texas for generations.”

In July, Aurora said it raised $820 million in capital to fuel its growth—growth that’s being accompanied by scrutiny.

In light of recent controversies surrounding self-driving vehicles, the International Brotherhood of Teamsters, whose union members include over-the-road truckers, recently sent a letter to Lt. Gov. Dan Patrick calling for a ban on autonomous vehicles in Texas.

“The Teamsters believe that a human operator is needed in every vehicle—and that goes beyond partisan politics,” the letter states. “State legislators have a solemn duty in this matter to keep dangerous autonomous vehicles off our streets and keep Texans safe. Autonomous vehicles are not ready for prime time, and we urge you to act before someone in our community gets killed.”

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.